Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
The company recently released Q3 results and highlights:
· Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
· Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
· Record 9 months revenues at $10.2 million , up 94%.
· Private and public reimbursement coverage expanding for Redesca®
· New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
Tags: BioSyent Inc., blood clot, CSE, HLS Therapeutics, investment, Knight Therapeutics, Medexus Pharmaceuticals, Redesca